Venus Medtech (Hangzhou) Inc. (VMTHF)
OTC Markets OTCPK · USD · Healthcare · Medical Devices
$0.1323 (+0.00%) as of
Key statistics
- Market cap
- 57.93M
- EPS (TTM)
- -0.1500
- Dividend yield
- 0.00%
- 52-week range
- 0.1323 – 0.4219
- Beta
- 1.11
- Revenue (TTM)
- 255.15M
- Profit margin
- -181.95%
- Volume
- 1.00k
About Venus Medtech (Hangzhou) Inc.
Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. The company's offers transcatheter aortic heart valve replacement products, such as VenusA-Valve, VenusA-Plus, VenusA-Pro, and VenusA-Deluxe; and VenusP-Valve, a transcatheter pulmonary valve system to treat patients suffering with moderate to severe pulmonary regurgitation with or without right ventricular outflow tract stenosis. It also develops Venus-Vitae, a balloon-expandable dry-tissue product; Venus-PowerX, a self-expanding dry-tissue product; Cardiovalve, a transcatheter valve replacement system for the treatment of patients with mitral regurgitation and in pivotal clinical trial for the treatment of patients with tricuspid regurgitation; and renal artery denervation ablation system for the treatment of hypertension. In addition, the company offers procedural accessories comprising catheter sheath product and balloon catheter. Venus Medtech (Hangzhou) Inc. was incorporated in 2009 and is headquartered in Hangzhou, the People's Republic of China.
- Sector
- Healthcare
- Industry
- Medical Devices
- Headquarters
- Hangzhou, China
- Employees
- 557
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.